A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: Effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 4, 2005, Pages 1953-1960

  Liu, Peter Y ^a   Hoey, Kelley A ^a   Mielke, Kristi L ^a   Veldhuis, Johannes D ^a   Khosla, Sundeep ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; ESTRADIOL; GONADORELIN AGONIST; LEUPRORELIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PROCOLLAGEN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MORPHOGENESIS; NORMAL HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OVARY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STEROIDOGENESIS;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BONE RESORPTION; CARRIER PROTEINS; COLLAGEN TYPE I; ESTRADIOL; FEMALE; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LEUPROLIDE; MEMBRANE GLYCOPROTEINS; MENOPAUSE; MIDDLE AGED; OSTEOCALCIN; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 17844400549     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1583     Document Type: Article

References (44)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, et al. 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
2. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
3. Cauley JAD, Robbins JMD, Chen ZP, Cummings SRMD, Jackson RDMD, LaCroix AZPMPH, LeBoff MMD, Lewis CEMDM, McGowan JP, Neuner JMDMPH, Pettinger MMS, Stefanick MLP, Wactawski-Wende JP, Watts NBMD, for the Women's Health Initiative I 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729-1738
4. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M 2003 Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 290:1042-1048
5. Hannon R, Blumsohn A, Naylor K, Eastell R 1998 Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124-1133
6. Hulley SB, Grady D 2004 The WHI estrogen-alone trial - do things look any better? JAMA 291:1769-1771
7. Turgeon JL, McDonnell DP, Martin KA, Wise PM 2004 Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304:1269-1273
8. Schlemmer A, Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C 1993 Possible variation in bone resorption during the normal menstrual cycle. Acta Endocrinol (Copenh) 129:388-392
9. Gorai I, Taguchi Y, Chaki O, Kikuchi R, Nakayama M, Yang BC, Yokota S, Minaguchi H 1998 Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 83:326-332
10. Gorai I, Chaki O, Nakayama M, Minaguchi H 1995 Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100-104
11. Massafra C, De Felice C, Agnusdei DP, Gioia D, Bagnoli F 1999 Androgens and osteocalcin during the menstrual cycle. J Clin Endocrinol Metab 84:971-974
12. Zittermann A, Schwarz I, Scheld K, Sudhop T, Berthold HK, von Bergmann K, van der Ven H, Stehle P 2000 Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab 85:95-101
13. Ho KK, Weissberger AJ 1992 Impact of short-term estrogen administration on growth hormone secretion and action: distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 7:821-827
14. Khosla S, Arrighi HM, Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL 2002 Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394-399
15. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, Green A, Dennerstein L 1999 Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 84:4025-4030
16. Wihlback AC, Sundstrom Poromaa I, Bixo M, Allard P, Mjorndal T, Spigset O 2004 Influence of menstrual cycle on platelet serotonin uptake site and serotonin 2A receptor binding. Psychoneuroendocrinology 29:757-766
17. Randolph Jr JF, Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ 2004 Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab 89:1555-1561
18. Grinspoon SK, Friedman AJ, Miller KK, Lippman J, Olson WH, Warren MP 2003 Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea. J Clin Endocrinol Metab 88:3651-3656
19. Pereda CA, Hannon RA, Naylor KE, Eastell R 2002 The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women. BJOG 109:812-820
20. Sands RH, Studd JW, Jones J, Alaghband-Zadeh J 2000 Comparison of the biochemical effects of testosterone and estrogen on bone markers in surgically menopausal women. Gynecol Endocrinol 14:382-387
21. Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Fox S, Chow J 2001 Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 86:289-295
22. Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Sims TJ, Bailey AJ 2001 Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 12:465-470
23. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560
24. Meier C, Liu PY, Ly LP, de Winter-Modzelewski J, Jimenez M, Handelsman DJ, Seibel MJ 2004 Recombinant human chorionic gonadotropin, but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 89:3033-3041
25. Chow JW, Lean JM, Chambers TJ 1992 17 β-estradiol stimulates cancellous bone formation in female rats. Endocrinology 130:3025-3032
26. Edwards MW, Bain SD, Bailey MC, Lantry MM, Howard GA 1992 17β Estradiol stimulation of endosteal bone formation in the ovariectomized mouse: an animal model for the evaluation of bone-targeted estrogens. Bone 13:29-34
27. Takano-Yamamoto T, Rodan GA 1990 Direct effects of 17 β-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci USA 87:2172-2176
28. Chesnut 3rd CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson Jr CC, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ 1997 Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29-37
29. Bjarnason NH, Byrjalsen I, Hassager C, Haarbo J, Christiansen C 2000 Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss. Am J Obstet Gynecol 183:550-560
30. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL 1993 Preventive effects of transdermal 17 β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 168:114-121
31. Giske LE, Hall G, Rud T, Landgren BM 2002 The effect of 17β-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women. Osteoporos Int 13:309-316
32. Naessen T, Berglund L, Ulmsten U 1997 Bone loss in elderly women prevented by ultralow doses of parenteral 17β-estradiol. Am J Obstet Gynecol 177:115-119
33. Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, Delmas PD 1999 Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 9:358-366
34. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR 1996 Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81:2848-2853
35. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO 1996 Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 81:2250-2256
36. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR 1988 Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-84
37. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86
38. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL 2003 Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221-1230
39. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140:4367-4370
40. Saika M, Inoue D, Kido S, Matsumoto T 2001 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142:2205-2212
41. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM 2002 Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550-1554
42. Szulc P, Delmas PD 2001 Biochemical markers of bone turnover in men. Calcif Tissue Int 69:229-234
43. Lim SK, Won YJ, Lee HC, Huh KB, Park YS 1999 A PCR analysis of ERα and ERβ mRNA abundance in rats and the effect of ovariectomy. J Bone Miner Res 14:1189-1196
44. Hoyland JA, Baris C, Wood L, Baird P, Selby PL, Freemont AJ, Braidman IP 1999 Effect of ovarian steroid deficiency on oestrogen receptor α expression in bone. J Pathol 188:294-303